A frequently cited concern regarding patient-as-own-control trial designs in rare disease is the potential for placebo and related effects to inflate apparent treatment efficacy. Whether this concern is disqualifying or manageable has not been systematically evaluated. We reviewed meta-analyses quantifying placebo effect magnitude by endpoint type, reporter modality, and trial duration and evaluated statistical methods available for post-trial placebo adjustment in own-control designs. Placebo effects depend heavily on endpoint type. For objective endpoints (enzyme activity, serum biomarkers, imaging volumetrics)-which constitute the majority of primary endpoints in approved rare disease therapies-placebo effects are consistently small and in most meta-analyses statistically indistinguishable from zero (standardized mean difference SMD < 0.10). For subjective endpoints (patient-reported pain, caregiver-rated function), effects are larger (SMD 0.20-0.50) but well-characterized and correctable. Placebo effects peak early and decay over weeks, providing a temporal signature distinguishable from sustained pharmacological effects. Multiple complementary analytical methods-including temporal trajectory modeling, objective-subjective concordance analysis, Bayesian informative priors, extended run-in observation designs, and blinded outcome assessment-are available to quantify and manage placebo contributions. Importantly, the randomized controlled trial's structural advantage in canceling placebo is itself degraded in small samples, where asymmetric allocation of placebo responders can distort between-arm comparisons. The placebo objection to own-control designs is manageable rather than disqualifying. For objective endpoints, correction is minimal. For subjective endpoints, a rich analytical toolkit supports credible decomposition of drug and placebo components. These findings support the broader adoption of own-control designs in rare disease clinical trials.
Summar et al. (Fri,) studied this question.